Related news from
Sun, 01 Nov 2026 02:08:15 +0000	Cencora (COR) Stock Still Looks Undervalued After Its 173% Run Cencora has put up a powerful long term share price performance, yet the current US$330.84 price invites a sharper question. Are the cash flows behind the business strong enough, and predictable enough, to make that level look well supported? Over the past 5 years the stock is up 172.6%, which puts a lot of weight on whether the underlying cash generation matches the market's enthusiasm. The planned US$2.4b purchase of American Oncology Network can reshape how quickly Cencora converts its...
Sun, 01 Nov 2026 01:14:02 +0000	Is Cencora (COR) Fully Valued Following Its $2.4b American Oncology Network Deal? Cencora (COR) has moved into the spotlight after agreeing to buy American Oncology Network in a deal valued at up to US$2.4b. The transaction reshapes its community cancer care footprint. Cencora’s latest move comes after a mixed run in the market, with the share price delivering a 7.05% 1 month return and a 7.29% 3 month share price return. Total shareholder return over 1 year has slipped 1.32% but climbed 172.57% over 5 years, suggesting that long term holders have seen strong compounding...
Sat, 31 Oct 2026 14:15:09 +0000	What Does Cencora (COR) Gain From Expanding Into 12 More States? Cencora (NYSE: COR) agreed to acquire American Oncology Network to expand its community-based cancer care footprint. The deal broadens Cencora's physician practice management services into 12 additional states through American Oncology Network's clinic footprint. American Oncology Network brings a network of oncology practices that operates primarily in community settings across the United States. Cencora's purchase of American Oncology Network reshapes its reach in community oncology, but...
Fri, 30 Oct 2026 13:57:00 +0000	Cencora Gears Up to Report Q4 Results: How to Play the Stock? COR's Q4 earnings are likely to benefit from strong specialty pharma demand and MSO growth, but pricing pressures and higher interest costs may weigh on results.
Fri, 30 Oct 2026 12:15:04 +0000	Unveiling Cencora (COR) Q4 Outlook: Wall Street Estimates for Key Metrics Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Cencora (COR), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2026.
Wed, 28 Oct 2026 13:00:12 +0000	Cencora (COR) Reports Next Week: Wall Street Expects Earnings Growth Cencora (COR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wed, 28 Oct 2026 12:37:00 +0000	Cencora to Acquire AON in $2.4B Deal to Expand Oncology Network COR's $2.4B acquisition of AON aims to expand its oncology services platform, strengthen community cancer care and support long-term growth.
Sat, 24 Oct 2026 01:28:19 +0000	Cencora's Q4 2026 Earnings: What to Expect Cencora is scheduled to release its fourth-quarter results next month, with analysts projecting double-digit earnings growth.
Wed, 21 Oct 2026 11:30:00 +0000	Cencora to Acquire American Oncology Network to Strengthen Support of Community Oncology CONSHOHOCKEN, Pa. & FORT MYERS, Fla., October 21, 2026--Cencora, Inc. (NYSE: COR) today announced it has signed a definitive agreement to acquire American Oncology Network, Inc. ("AON") (OTCQX: AONC), a physician-led network of more than 350 oncology providers across 21 states.
Sat, 24 Oct 2026 00:21:12 +0000	Is American Oncology Network (AONC) Fully Valued Following Cencora's $2.4b Buyout Deal? Cencora (COR) has moved to take control of American Oncology Network (OTCPK:AONC) by signing a deal to acquire the remaining 96% it does not own for an enterprise value of $2.4b. American Oncology Network’s share price has surged in recent weeks, with a 7 day and 30 day share price return of about 100% and a 1 year total shareholder return of 149.26%. This suggests the Cencora offer has sharply reset expectations around the stock’s value and risk profile. Spot similar healthcare momentum by...
Mon, 02 Nov 2026 16:20:02 +0000	AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy for 2027? AbbVie boasts faster revenue growth and stronger cash generation, while Bristol Myers trades at half the valuation multiple, a classic growth-versus-value showdown.
Fri, 30 Oct 2026 15:07:29 +0000	2 large-cap stocks with impressive fundamentals and 1 we ignore Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit growth as expanding further becomes an increasingly challenging task.
Fri, 30 Oct 2026 10:49:53 +0000	Is Buying McKesson Stock Near Its High A Bad Idea? For questions about this article or underlying research, email help@trefis.com.
Thu, 29 Oct 2026 20:29:16 +0000	Is It A Mistake To Buy Cardinal Health Stock At A High? For questions about this article or underlying research, email help@trefis.com.
Thu, 29 Oct 2026 13:00:22 +0000	Will Biodesix, Inc. (BDSX) Report Negative Earnings Next Week? What You Should Know Biodesix (BDSX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tue, 20 Oct 2026 21:35:02 +0000	AbbVie vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? AbbVie generates $17.8 billion in annual free cash flow but faces patent cliffs, while Vertex boasts a 33% net margin with concentrated cystic fibrosis exposure.
Tue, 27 Oct 2026 15:10:02 +0000	Amgen vs. Novo Nordisk: Which Healthcare Giant's Stock Is a Better Buy in 2026? Amgen's 9.9% revenue growth outpaces Novo Nordisk, but a 33.1% net margin and lower valuation multiples tell a different profitability story.
Sat, 24 Oct 2026 16:31:01 +0000	Amgen vs. Johnson & Johnson: Which Healthcare Giant Has the Better Stock to Buy? Amgen trades at a lower valuation multiple, but Johnson & Johnson's fortress balance sheet and stronger free cash flow tell a different story about financial resilience.
Thu, 22 Oct 2026 22:15:02 +0000	Amgen vs. Eli Lilly: Does the GLP-1 Mania Make LLY Stock a Better Buy in 2026? Amgen trades at half the valuation multiple of Eli Lilly while generating stronger free cash flow, but explosive growth in obesity drugs tells a different story.
Tue, 20 Oct 2026 22:05:02 +0000	Amgen vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026? Amgen boasts stronger revenue growth, while Bristol Myers Squibb generates nearly 60% more free cash flow at half the valuation.

If you are already a Value Forum member but are not logged on, click here to log on. If you are a guest, thank you for visiting ValueForum -- click here for information about guest access or click here to join -- a Trial Pass can be purchased for $6.99 to help you decide if you want to commit to longer term membership. Did you know there are customized portals into VF like REITs.ValueForum.com and also My ValueForum which lets you customize your VF experience to the posters and topics that most interest you!